Both Innovent and Ascentage have yet to log any revenues. ETPrimeWe rummaged through some Fortis files. What we found isn’t pretty. HONG KONG: Two Chinese biotechs have axed plans to list in New York and instead aim to raise up to $800 million in Hong …
( read original story …)